Skip to main content
Clinical Trials/IRCT2017032633143N1
IRCT2017032633143N1
Recruiting
Phase 2

Evalute and compare the effectiveness of oral thalidomide + Bortezomib (subcutaneous) + Dexamethasone(IV) regimen with Bortezomib (subcutaneous) + oral prednisolone + oral thalidomide regimen in patients with newly diagnosed multiple myeloma

Personal0 sites30 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Personal
Enrollment
30
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Personal

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed patients with multiple myeloma who have over 18 years of age and are willing to participate in this study.
  • Exclusion criteria: HIV\-positive patients, patients with a history of malignant, uncontrolled diabetes, neuropathy grade 2 diabetes, significant liver and kidney and heart failure are excluded.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials